Neuren thinks big

By Dylan Bushell-Embling
Wednesday, 16 July, 2008

Neuren Pharmaceuticals [ASX: NEU] has concluded patient recruitment and dosing for its Phase III clinical trial of Glypromate, a therapeutic designed to reduce brain impairment after major heart surgery.

The recruitment of 320 patients has been concluded ahead of schedule, and Neuren is expecting to release provisional efficacy results before the end of the year.

Up to a third of patients suffer cognitive impairment three months after major heart surgery, and there is currently no approved treatment to prevent it.

Content from other channels on our network

Food safety recalls in NZ: the 2025 report

From raw to rare sugar: low-cal sweetener under development

Upcycling cauliflower waste into protein ingredients for future food

Lolly factory celebrates 50 years with new technology installed

Keeping pace with changing appetites

Unify risk and compliance to protect patients.

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available

Siemens expands Fusesaver manufacturing facility

BESS project provides long-duration battery for NSW

Lessons in long-distance telemetry

GECA and ACOR launch national standard for recycling

Antibiotics in wastewater may contribute to antimicrobial resistance

Neuren thinks big

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network